异常发现随访连续性 / Abnormal Finding Follow-up Continuity

Definition

Abnormal finding follow-up continuity is the principle that a known screening abnormality stays in an explicit surveillance or care pathway until qualified reassessment changes that plan.

Current Synthesis

VOL.139 applies the principle to lung, thyroid, breast, and other nodules. Budget-aware package rotation can be reasonable for people without unresolved findings, but it becomes unsafe when a prior abnormality is simply dropped from the next annual plan. Category change, growth, symptoms, or other risk signals can shorten intervals or trigger additional imaging, while stability can support continued observation under an individualized plan.

VOL.135 broadens continuity beyond nodules: carotid plaque and old infarction redirect attention to vascular-risk control; uncertain brain-imaging signals may need better imaging or symptom correlation; low-risk gallbladder, thyroid, bone-density, urinary, skin, and venous findings can require different repeat tests or specialist routes. Continuity does not mean repeating every test forever. It means preserving the finding, reason, comparison baseline, risk-control work, interval, and escalation rule until qualified reassessment changes or closes the plan.

VOL.106 makes comparability itself part of continuity. In pulmonary-nodule follow-up, different readers or institutions can produce small measurement differences that create anxiety without proving biological change. Preserving prior images and using a comparable follow-up setting can improve longitudinal interpretation, while stable findings may eventually move to longer intervals. The same episode warns that an incidental nodule should not automatically absorb a separate symptom such as chest tightness.

Key Claims

• A prior abnormal finding changes the next checkup from fresh screening to longitudinal surveillance.
• Annual budget or package rotation should not silently break an indicated follow-up chain.
• Trend and category change are often more informative than one isolated image or measurement.
• Follow-up intensity can increase, decrease, or end according to qualified reassessment.
• The plan should preserve what to repeat or monitor, when to do it, which modifiable risks matter, and what change triggers escalation.
• Comparable prior images, measurement context, and separation of incidental findings from new symptoms can prevent false trend narratives.

Evidence

• Nodule continuity: VOL.139当代打工人体检指南：如何选项目？如何避坑？报告怎么看？公立医院医生来支招 warns against replacing an already abnormal lung, thyroid, or breast item with unrelated tests in the next annual package.
• Escalation by change: VOL.139当代打工人体检指南：如何选项目？如何避坑？报告怎么看？公立医院医生来支招 connects increased category or risk with shorter intervals or additional mammography, MRI, or other clinician-selected assessment.
• Longitudinal health management: VOL.139当代打工人体检指南：如何选项目？如何避坑？报告怎么看？公立医院医生来支招 frames a normal or abnormal checkup as a point in an ongoing process rather than a completed exam event.
• Organ-specific continuity: VOL.135直面体检｜医生们带你看懂报告里的惊悚指标 distinguishes repeat imaging, laboratory confirmation, vascular-risk control, specialist assessment, and symptom-triggered escalation across multiple systems.
• Confirmation before commitment: VOL.135直面体检｜医生们带你看懂报告里的惊悚指标 notes that limited screening images or isolated urine findings may need confirmation before they become a stable diagnosis or treatment path.
• Comparison quality and symptom separation: VOL.106胸外科｜王兴：病人家属问我怎么能够讨好医生｜胸闷、气胸、肺结节问题回答篇 connects pulmonary-nodule surveillance to comparable imaging, possible measurement variation, time-based reassessment, and independent evaluation of chest tightness.

Counterevidence & Qualifications

Not every incidental finding needs repeated imaging, and unnecessary surveillance can itself create radiation, procedures, cost, and anxiety. Follow-up can also mean risk-factor management or symptom observation rather than another scan. Comparable imaging can reduce noise but does not guarantee identical measurement or justify delaying assessment of progressive symptoms. The appropriate interval, modality, treatment threshold, and stopping rule depend on the exact finding, classification system, patient risk, prior comparison, and clinician judgment.

What Changed

• Added comparable imaging and measurement context to longitudinal surveillance.
• Clarified that a known incidental finding should not automatically explain a separate or worsening symptom.

Related Concepts

• Diagnostic Safety Netting / 诊断安全网 - broader follow-up design for unresolved clinical uncertainty.
• 体检结果情境化解读 / Screening Result Interpretation - process that determines whether a finding needs observation or escalation.
• 个体化预防性体检选择 / Individualized Preventive Checkup Selection - package selection process constrained by prior abnormalities.
• Preventive Health Screening - broader early-detection workflow.
• Endoscopy Pathology and Follow-up / 内镜病理与复诊闭环 - adjacent example where findings create a longitudinal care obligation.
• 肺结节随访 / Pulmonary Nodule Surveillance - focused application to lung-nodule comparison, interval review, and escalation.